MEMO Therapeutics AG closes Series A2 financing round of CHF 5 million to advance its antibody discovery programs into preclinical and clinical development
MEMO Therapeutics AG ("MEMO"), an innovator in the field of antibody discovery and human immune repertoire analysis, announced on May 9, 2018, the closing of a Series A2 financing round of CHF 5.0 million.